In last trading session, Ocular Therapeutix Inc (NASDAQ:OCUL) saw 2.35 million shares changing hands with its beta currently measuring 1.42. Company’s recent per share price level of $9.46 trading at $0.27 or 2.94% at ring of the bell on the day assigns it a market valuation of $1.51B. That closing price of OCUL’s stock is at a discount of -24.42% from its 52-week high price of $11.77 and is indicating a premium of 38.9% from its 52-week low price of $5.78. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.19 million shares which gives us an average trading volume of 2.06 million if we extend that period to 3-months.
For Ocular Therapeutix Inc (OCUL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.08. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Ocular Therapeutix Inc (NASDAQ:OCUL) trade information
Upright in the green during last session for gaining 2.94%, in the last five days OCUL remained trading in the green while hitting it’s week-highest on Tuesday, 06/24/25 when the stock touched $9.46 price level, adding 0.73% to its value on the day. Ocular Therapeutix Inc’s shares saw a change of 44.87% in year-to-date performance and have moved 13.57% in past 5-day. Ocular Therapeutix Inc (NASDAQ:OCUL) showed a performance of 36.31% in past 30-days. Number of shares sold short was 14.42 million shares which calculate 5.95 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 19 to the stock, which implies a rise of 50.21% to its current value. Analysts have been projecting 19 as a low price target for the stock while placing it at a high target of 19. It follows that stock’s current price would drop -100.85% in reaching the projected high whereas dropping to the targeted low would mean a loss of -100.85% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 8.51% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -17.19% while estimates for its earnings growth in next 5 years are of 4.61%.
Ocular Therapeutix Inc (NASDAQ:OCUL)’s Major holders
Insiders are in possession of 3.82% of company’s total shares while institution are holding 87.01 percent of that, with stock having share float percentage of 90.46%. Investors also watch the number of corporate investors in a company very closely, which is 87.01% institutions for Ocular Therapeutix Inc that are currently holding shares of the company. SUMMER ROAD LLC is the top institutional holder at OCUL for having 14.89 million shares of worth $101.82 million. And as of 2024-06-30, it was holding 8.9767 of the company’s outstanding shares.
The second largest institutional holder is VR ADVISER, LLC, which was holding about 12.76 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.6964 of outstanding shares, having a total worth of $87.3 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 4.71 shares of worth $44.56 million or 2.96% of the total outstanding shares. The later fund manager was in possession of 3.91 shares on Apr 30, 2025 , making its stake of worth around $37.01 million in the company or a holder of 2.46% of company’s stock.
